Tandutinib (MLN518) reverses multidrug resistance by inhibiting the efflux activity of the multidrug resistance protein 7 (ABCC10)
Tóm tắt
Từ khóa
Tài liệu tham khảo
Wu, 2008, Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies, Curr Mol Pharmacol, 1, 93, 10.2174/1874467210801020093
Bradbury, 2004, DNA repair pathways in drug resistance in melanoma, Anticancer Drugs, 15, 421, 10.1097/01.cad.0000127665.74096.93
Deeley, 2006, Transmembrane transport of endo-and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins, Physiol Rev, 86, 849, 10.1152/physrev.00035.2005
Borges-Walmsley, 2003, Structure and function of efflux pumps that confer resistance to drugs, Biochem J, 376, 313, 10.1042/bj20020957
Sodani, 2012, Multidrug resistance associated proteins in multidrug resistance, Chin J Cancer, 31, 58, 10.5732/cjc.011.10329
Chen, 2011, Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases, FEBS J, 278, 3226, 10.1111/j.1742-4658.2011.08235.x
Naramoto, 2007, Multidrug resistance-associated protein 7 expression is involved in cross-resistance to docetaxel in salivary gland adenocarcinoma cell lines, Int J Oncol, 30, 393
Hopper-Borge, 2004, Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel, Cancer Res, 64, 4927, 10.1158/0008-5472.CAN-03-3111
Hopper-Borge, 2009, Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epithilone B, Cancer Res, 69, 178, 10.1158/0008-5472.CAN-08-1420
Zhou, 2009, Cepharanthine is a potent reversal agent for MRP7 (ABCC10)-mediated multidrug resistance, Biochem Pharmacol, 77, 993, 10.1016/j.bcp.2008.12.005
Mendelsohn, 2003, Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer, J Clin Oncol, 21, 2787, 10.1200/JCO.2003.01.504
Hirota, 1998, Gain-of-function mutations of c-KIT in human gastrointestinal stromal tumors, Science, 279, 577, 10.1126/science.279.5350.577
Shah, 2002, Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia, Cancer Cell, 2, 117, 10.1016/S1535-6108(02)00096-X
Jordanides, 2006, Functional ABCG2 is overexpressed on primary CML CD34+cells and is inhibited by imatinib mesylate, Blood, 108, 1370, 10.1182/blood-2006-02-003145
Schittenhelm, 2006, Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies, Cancer Res, 66, 473, 10.1158/0008-5472.CAN-05-2050
Hiwase, 2008, Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications, Clin Cancer Res, 14, 3881, 10.1158/1078-0432.CCR-07-5095
Gora-Tybor, 2008, Targeted drugs in chronic myeloid leukemia, Curr Med Chem, 15, 3036, 10.2174/092986708786848578
Zhang, 2012, The Blk pathway functions as a tumor suppressor in chronic myeloid leukemia stem cells, Nat Genet, 44, 861, 10.1038/ng.2350
Shi, 2007, Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance, Cancer Res, 67, 11012, 10.1158/0008-5472.CAN-07-2686
Dai, 2008, Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2, Cancer Res, 68, 7905, 10.1158/0008-5472.CAN-08-0499
Tiwari, 2009, Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXP transporters, Biochem Pharmacol, 78, 153, 10.1016/j.bcp.2009.04.002
Shen, 2009, Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7(ABCC10), PLoS One, 4, e7520, 10.1371/journal.pone.0007520
Kuang, 2009, Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance, Biochem Pharmacol, 79, 154, 10.1016/j.bcp.2009.08.021
DeAngelo, 2006, Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics, Blood, 108, 3674, 10.1182/blood-2006-02-005702
Chen, 2003, Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10), Mol Pharmacol, 63, 351, 10.1124/mol.63.2.351
Bliss, 1935, The calculation of the dose-mortality curve, Ann Appl Biol, 22, 134, 10.1111/j.1744-7348.1935.tb07713.x
Tiwari, 2012, Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models, Cancer Lett, 328, 307, 10.1016/j.canlet.2012.10.001
Yang, 2010, P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor, Drug Metab Lett, 4, 201, 10.2174/187231210792928279
Kantarjian, 2006, Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL, New Eng J Med, 354, 2542, 10.1056/NEJMoa055104